BioPorto Advances U.S. Validation Study for Adult AKI Biomarker
Event summary
- BioPorto activated its first U.S. clinical site for the ProNephro AKI® U.S. Adult Urine NGAL Validation Study on August 18, 2026.
- The study aims to validate the clinical performance of ProNephro AKI (NGAL) for risk assessment of moderate to severe Acute Kidney Injury (AKI) in adult ICU patients.
- Dr. Andrew Allegretti of Massachusetts General Hospital continues as National Principal Investigator for the study.
- This follows BioPorto’s recently completed adult AKI cut-off study and is part of its FDA regulatory pathway for adult indications in the U.S.
The big picture
BioPorto’s advancement of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study is a critical step in expanding its biomarker-based diagnostic tools into the U.S. adult market. The study’s success could strengthen BioPorto’s position in the competitive landscape of AKI diagnostics, where early intervention is key to improving patient outcomes. The collaboration with Dr. Andrew Allegretti and Massachusetts General Hospital underscores the strategic importance of leveraging established clinical relationships to navigate the FDA regulatory pathway.
What we're watching
- Study Execution
- The pace at which BioPorto activates remaining clinical sites and enrolls patients will determine the timeline for validation results.
- Regulatory Pathway
- Whether the study results will support BioPorto’s FDA regulatory pathway for adult indications in the U.S.
- Market Expansion
- How successful validation could position BioPorto to expand its NGAL biomarker tests into the U.S. adult AKI market.